The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer.
Gayle S. Jameson
No relevant relationships to disclose
Daniel D. Von Hoff
Research Funding - Lilly
Glen J. Weiss
Consultant or Advisory Role - Lilly
Donald A. Richards
No relevant relationships to disclose
David A. Smith
Honoraria - Lilly
Research Funding - Lilly
Carlos Becerra
Honoraria - Lilly
Research Funding - Lilly
Mitchell C. Benson
No relevant relationships to disclose
Zheng Yuan
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Deborah A Robins
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael Turik
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Margaret Wagner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Leijun Hu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Boris K. Lin
Employment or Leadership Position - Lilly
Stock Ownership - Lilly